Intent-to-Treat

Table of Contents

Definition

Why ITT Matters in Clinical Trials

Intent-to-Treat (ITT) plays a critical role in the conduct and oversight of modern clinical trials. Understanding this concept is essential for sponsors, investigators, clinical operations teams, and regulatory professionals who manage the complexity of bringing new therapies from bench to bedside.

A statistical analysis strategy in which all participants randomized in a clinical trial are included in the analysis, regardless of whether they completed the study or adhered to the protocol. ITT analysis preserves the benefits of randomization and provides a conservative estimate of treatment effect. The importance of itt extends across all phases of clinical development, from early-phase safety studies through large-scale confirmatory trials and post-marketing surveillance.

Key Aspects of ITT

  • Regulatory alignment — ITT must comply with applicable regulations including ICH GCP, FDA requirements, and regional guidelines
  • Documentation — All activities related to itt must be thoroughly documented with complete audit trails
  • Quality assurance — Robust quality management processes ensure that itt meets predefined standards and specifications
  • Training — All personnel involved must receive adequate training and demonstrate competency before performing itt-related activities
  • Technology integration — Modern clinical trial platforms streamline itt through automation, real-time monitoring, and centralized data management

Regulatory Framework

Regulatory authorities worldwide have established clear expectations for itt in clinical trials. The FDA, EMA, and other health authorities evaluate compliance with these standards during routine inspections, pre-approval inspections, and for-cause audits. Non-compliance can result in regulatory actions including warning letters, clinical holds, data rejection, or delays in marketing approval.

For detailed regulatory guidance, refer to the official documentation from the relevant regulatory authority.

Common Challenges

  • Maintaining consistency across multiple sites and regions with varying local requirements
  • Ensuring timely execution while meeting all quality and compliance standards
  • Managing the volume and complexity of documentation throughout the trial lifecycle
  • Coordinating communication between sponsors, CROs, sites, and regulatory authorities
  • Adapting to evolving regulatory expectations and industry best practices

Best Practices

  1. Establish clear SOPs and work instructions for all itt-related activities before trial initiation
  2. Leverage technology platforms that provide built-in compliance controls and automated workflows
  3. Implement risk-based approaches to focus resources on the most critical aspects
  4. Conduct regular training and competency assessments for all involved personnel
  5. Maintain real-time visibility through dashboards and reporting tools to identify issues early
  6. Perform periodic quality reviews to ensure ongoing compliance and drive continuous improvement
Back to Glossary

Simplify clinical operations

Ready to modernize your clinical trials?

See how Clincove unifies EDC, eISF, eTMF, and eSource into one platform -- deploy in weeks, not months.

21 CFR Part 11 Compliant HIPAA & GDPR Deploy in weeks

Have Questions?

Have questions about Clincove? We're here to help you find the right solution for your clinical trial needs.

Personalized platform walkthrough
Discuss your specific trial needs
No commitment required
FDA 21 CFR Part 11
HIPAA & GDPR compliant
You're subscribed!